___

• Rauenzahn S, Del Fabbro E. Opioid management of pain: the impact of the
• prescription opioid abuse epidemic. Curr Opin Support Palliat Care 2014;
• :273-8.
• National Institute on Drug Abuse Research Report Series – prescription
• drugs: abuse and addiction. 2011. Available at http://www.drugabuse.gov/
• sites/default/files/rrprescription.pdf. (Accessed 18 April 2014)
• Vital signs: overdoses of prescription opioid pain relievers – United
• States,1999–2008. MMWR 2011;60;1487-1492.
• Kaasa S, Mercadante S, Caraceni A. Cancer pain--progress and ongoing
• issues in Europe. Pain Res Manag 2009; 14:353-355.
• Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief
• Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983;
• :197-210.
• Wang XS, Cleeland CS. Outcomes measurement in cancer pain. In: Pain
• Management: Evidence, Outcomes, and Quality of Life. A Sourcebook --
• Wittink HM, Carr DB, eds. London: Elsevier 2008; 361-76.
• Casty F.E, Wieman M.S, Shusterman N. Current Topics in Opioid Therapy
• for Pain Management: Addressing the Problem of Abuse. Clin Drug Investig
• ; 33:459–468.
• US Department of Justice. Promoting pain relief and preventing abuse of
• pain medications: a critical balancing act. 2012. http://www.deadiversion.
• usdoj.gov/pubs/advisories/painrelief.pdf. Accessed 6 Apr 2012.
• Centers for Disease Control and Prevention. Vital signs: overdoses of
• prescription opioid pain relievers—United States, 1999–2008. MMWR
• Wkly. 2011;60(43):1487–92.
• Atzpodien J, Royston P, Wandert T, Reitz M, and German Cooperative
• Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal
• carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348–53.
• Suh SY, Ahn HY. Lactate dehydrogenase as a prognostic factor for survival
• time of terminally ill cancer patients: a preliminary study. Eur J Cancer
• ;43:1051-9.
• Walenta S, Mueller-Klieser WF. Lactate:Mirror and motor of tumor
• malignancy. Semin Radiat Oncol 2004;14: 267–74.
• Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang
• NJ. Factors predictive of survival among 337 patients with mesothelioma
• treated between 1984 and 1994 by the cancer and leukemia group B.
• Chest 1998;113:723–31.
• Butt AA, Michaels S, Greer D, Clark R, Kissinger P, Martin DH. Serum LDH
• level as a clue to the diagnosis of histoplasmosis. AIDS Read 2002;12:317–
• Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii
• pneumonia, tuberculosis, and bacterial pneumonia. Chest 1995;108:415–
• Malbotra P, Sidhu LS, Singh SP. Serum lactate dehydrogenase level in
• various malignancies. Neoplasma 1986;33:641–7.
• Jin Y, Ye X, Shao L, Lin BC, He CX, Zhang BB, Zhang YP. Serum lactic
• dehydrogenase strongly predicts survival in metastatic nasopharyngeal
• carcinoma treated with palliative chemotherapy. Eur J Cancer
• ;49:1619-26.
• Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. Markers of
• bone metabolism and survival in men with hormone-refractory metastatic
• prostate cancer. Clin Cancer Res 2006;12:3361–7.
• Brown JE, Cook RJ, Lipton A, Coleman RE. Serum lactate dehydrogenase is
• prognostic for survival in patients with bone metastases from breast cancer:
• a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res
• ; 15;18:6348-55.